5α-pregnan-3α-ol-20-one

Ligand id: 4108

Name: 5α-pregnan-3α-ol-20-one

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 37.3
Molecular weight 318.26
XLogP 6.1
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
As the INN brexanolone (research code SAGE-547), this drug was approved by the FDA in March 2019, indicated for the treatment of moderate to severe postpartum depression [1]. Brexanolone has to be delivered as a continuous i.v. infusion (over a period of 60 hours), and this must only be carried out by a health care provider in a certified health care facility. In the US brexanolone is only available through a restricted distribution program called the Zulresso REMS Program.